Document is current
Any future updates will be listed below
-
Authors
Alban, Tyler J. https://orcid.org/0000-0002-3261-140X
Riaz, Nadeem https://orcid.org/0000-0001-9873-5862
Parthasarathy, Prerana
Makarov, Vladimir https://orcid.org/0000-0002-4104-5876
Kendall, Sviatoslav https://orcid.org/0000-0002-5368-5109
Yoo, Seong-Keun https://orcid.org/0000-0002-8749-7050
Shah, Rachna
Weinhold, Nils
Srivastava, Raghvendra https://orcid.org/0000-0001-6545-3957
Ma, Xiaoxiao
Krishna, Chirag
Mok, Juk Yee
van Esch, Wim J. E. https://orcid.org/0000-0002-7077-4349
Garon, Edward https://orcid.org/0000-0001-7077-8801
Akerley, Wallace
Creelan, Benjamin https://orcid.org/0000-0002-2728-8070
Aanur, Nivedita
Chowell, Diego
Geese, William J.
Rizvi, Naiyer A.
Chan, Timothy A. https://orcid.org/0000-0002-9265-0283
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA205426, R35 CA232097)
- License Information
-
More Information
Article History
Received: 7 November 2023
Accepted: 8 August 2024
First Online: 30 September 2024
Competing interests
: T.A.C. is a cofounder of and holds equity in Gritstone Oncology. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. T.A.C. has served as an advisor for Bristol-Myers Squibb, MedImmune, Illumina, Eisai, AstraZeneca and An2H. T.A.C. is an inventor on intellectual property and a patent held by MSKCC on using tumor mutational burden to predict immunotherapy response, which has been licensed to PGDx. The other authors declare no competing interests.
